{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04237623",
            "orgStudyIdInfo": {
                "id": "NSH 1246"
            },
            "organization": {
                "fullName": "Northside Hospital, Inc.",
                "class": "OTHER"
            },
            "briefTitle": "GM-CSF With Post-Transplant Cyclophosphamide",
            "officialTitle": "Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post-Infusion of T-Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells and With Post Transplant Cyclophosphamide",
            "therapeuticArea": [
                "Other"
            ],
            "study": "gm-csf-with-post-transplant-cyclophosphamide"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2020-05-18",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-09-18",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-09-18",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-01-17",
            "studyFirstSubmitQcDate": "2020-01-17",
            "studyFirstPostDateStruct": {
                "date": "2020-01-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Northside Hospital, Inc.",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Given the increased number of HLA-mismatched haploidentical transplantation with post-transplant cyclophosphamide performed each year and the high risk of infectious complications associated with this type of transplant, the investigators suggest that GM-CSF administration post-infusion of T-replete haploidentical stem cells and post-transplant cyclophosphamide can yield similar count recovery rates to G-CSF with a potential of lowering risk of infectious complications."
        },
        "conditionsModule": {
            "conditions": [
                "Transplant-Related Hematologic Malignancy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "SUPPORTIVE_CARE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 38,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "GM-CSF post-transplant",
                    "type": "EXPERIMENTAL",
                    "description": "Sargramostim (GM-CSF) will start on Day +5 and continue until ANC \\>1000 x3 days or \\>1500 x1 day. GM-CSF will be administered not less than 24 hours after the last dose of cyclophosphamide and will be given at a dose of 250mcg/m2/day as an infusion over 2 hours.",
                    "interventionNames": [
                        "Drug: Sargramostim",
                        "Other: Control Arm"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Sargramostim",
                    "description": "250mcg/m2/day IV starting Day +5",
                    "armGroupLabels": [
                        "GM-CSF post-transplant"
                    ],
                    "otherNames": [
                        "GM-CSF"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Control Arm",
                    "description": "Standard G-CSF given to those who decline to receive GM-CSF",
                    "armGroupLabels": [
                        "GM-CSF post-transplant"
                    ],
                    "otherNames": [
                        "G-CSF"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "The number of patients who achieved neutrophil engraftment at 20 days after the initiation of treatment.",
                    "description": "The aim of the study is to establish equivalent effectiveness of Sargramostim to a matched control cohort of G-CSF treated patients in time to achieve neutrophil (ANC \\>500 x3 days) post infusion of HLA-mismatched peripheral blood haploidentical stem cells with post-transplant cyclophosphamide. Patients will be followed for 3 months following the initiation of treatment to see engraftment numbers at 20 days after initial treatment.",
                    "timeFrame": "3 months after initial treatment"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "How many patients are still alive measured by overall survival at 12 months following the initiation of treatment.",
                    "description": "To estimate overall survival",
                    "timeFrame": "12 months following initiation of treatment"
                },
                {
                    "measure": "How many patients have not relapsed measured by relapse rates at 12 months following the initiation of treatment.",
                    "description": "To estimate relapse rates",
                    "timeFrame": "12 months following initiation of treatment"
                },
                {
                    "measure": "How many patients develop graft-versus-host-disease (GVHD) measured by the incidence of GVHD at 12 months following initiation of treatment",
                    "description": "To estimate incidence of GVHD",
                    "timeFrame": "12 months following initiation of treatment"
                },
                {
                    "measure": "How many patients have not relapsed measured by progression-free survival at 12 months following the initiation of treatment",
                    "description": "To estimate non-relapse mortality",
                    "timeFrame": "12 months following initiation of treatment"
                },
                {
                    "measure": "How many patients died due to infections measured by the incidence and type of infections at 12 months following initiation of treatment",
                    "description": "To estimate infection-related mortality",
                    "timeFrame": "12 months following initiation of treatment"
                },
                {
                    "measure": "How many patients died due to a treatment-related adverse events grade 2 or greater as assessed by CTCAE v.4.0",
                    "description": "To estimate event-free survival",
                    "timeFrame": "12 months following initiation of treatment"
                },
                {
                    "measure": "Number of patients to achieve full donor chimerisms at Days 30, 50, 100, and 6 months post-transplant as measured by donor chimerism data",
                    "description": "To estimate graft failure",
                    "timeFrame": "12 months following initiation of treatment"
                },
                {
                    "measure": "Number of patients that acquired an infection in the first 100-days post-transplant as measured by the incidence of infections",
                    "description": "To estimate the rate of infections",
                    "timeFrame": "12 months following initiation of treatment"
                },
                {
                    "measure": "Number of patients achieving platelet engraftment as measured by platelets reaching 20,000 without transfusion for 7 days",
                    "description": "To assess time to platelet engraftment",
                    "timeFrame": "12 months following initiation of treatment"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Availability of 5/10 to 8/10 matched related donor\n* KPS \\>/= 70%\n* CML, AML, MDS, ALL, CLL, HD, NHL, MPS/CMML, MM, any other hematologic condition deemed an eligible indication for allogeneic transplant by the treating center\n\nExclusion Criteria:\n\n* Poor cardiac, pulmonary, liver, and renal function\n* HIV-positive\n* Patients who have a debilitating medical or psychiatric illness that would preclude them from giving informed consent\n* History of severe or serious allergic reaction to human GM-CSF or yeast-derived products",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "78 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Stacey Brown, BA",
                    "role": "CONTACT",
                    "phone": "404-780-7965",
                    "email": "stacey.brown@northside.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Melhem Solh, MD",
                    "affiliation": "Northside Hospital",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Northside Hospital",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30342",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Stacey Brown, BA",
                            "role": "CONTACT",
                            "phone": "404-780-7965",
                            "email": "stacey.brown@northside.com"
                        },
                        {
                            "name": "Caitlin Guzowski, MBA, MHA",
                            "role": "CONTACT",
                            "phone": "404-851-8523",
                            "email": "caitlin.guzowski@northside.com"
                        },
                        {
                            "name": "H. Kent Holland, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Asad Bashey, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Lawrence E Morris, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Scott Solomon, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Melhem Solh, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000019337",
                    "term": "Hematologic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21314",
                    "name": "Hematologic Neoplasms",
                    "asFound": "Hematologic Malignancies",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000081222",
                    "term": "Sargramostim"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "relevance": "LOW"
                },
                {
                    "id": "M257633",
                    "name": "Molgramostim",
                    "relevance": "LOW"
                },
                {
                    "id": "M219218",
                    "name": "Sargramostim",
                    "asFound": "Irradiation",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}